.
New Delhi, April 26 (MondayMirror.com) The Drugs Controller General of India (DCGI) on Tuesday approved the restricted emergency use authorisation (EUA) to Bharat Biotech’s Covaxin for children between the age of 6-12 years, sources said.
The DGCI has asked vaccine manufacturer to submit safety data including the data on adverse event with due analysis every 15 days for the first two months and monthly thereafter upto 5 months, said the source familiar with the development.
This development comes after the Subject Expert Committee (SEC) discussed recommendations for the restricted emergency use of Covaxin in children aged between 2-12 years.
However, the SEC, after a meeting on Thursday, had recommended restricted emergency use of Biological E’s Covid-19 vaccine, Corbevax, in children aged 5-12 years.
Source: IANS
Christian pastors and leaders gathered across national borders on Thursday for an international program addressing…
A 25-year-old man with relapsed Acute Lymphoblastic Leukemia (ALL) involving the central nervous system has…
The book explores love, relationships, loss, resilience and the courage to begin again Chandigarh, September…
For years, Bollywood followed a fairly predictable formula when it came to movie franchises. A…
Unexpected expenses can put immediate pressure on household finances, particularly when savings are not enough…
Renowned corporate professional and Regional Council Member of NIRC of ICSI CS Arjun Tyagi, while…